Form 4: Assembly Biosciences CEO Sells Shares to Cover Tax Obligations

Assembly Biosciences CEO Jason A. Okazaki sold 392 shares of common stock on March 27, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

Summary

• On March 27, 2024, Jason A. Okazaki, CEO and President of Assembly Biosciences, sold 392 shares of common stock at a price of $12.87 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of restricted stock units.
• This transaction was mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors, requiring a 'sell-to-cover' transaction for tax obligations.
• Following the transaction, Okazaki directly owns 14,180 shares of Assembly Biosciences common stock.
• The reported holdings reflect an equitable adjustment due to a 1-for-12 reverse stock split that occurred on February 9, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale for tax purposes, which is neither particularly positive nor negative.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential sentiment.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it is a routine sale to cover tax obligations.

Key Dates